Parkinson-kór: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• SNCA 10
• LRRK2 7
• NRF2 1
• GBA1 13
• NLRP3 1
• PINK1 1
• AKT 0
• PI3K 0
• GLP-1 0
• STING 0
• BDNF 1
• mTOR 0
• SIRT1 0
• TLR4 0
• PPAR 0
• AMPK 1
• TP53 0
• GPX4 0
• MAPK 0
• MAPT 0
• TNF 0
• APOE 1
• HMGB1 0
• JNK 0
• ERK 0
• HSP90 1
• JAK 0
• STAT3 0
• TREM2 0
• HDAC 0
• TDP-43 1
• NMDA 0
• TFEB 0
• HIF-1 1
• IL-1 0
• PARP 0
• CTNNB1 0
• GIP 0
• IL-17 0
• PCSK9 0
• ACE2 0
• AQP4 0
• BCL-2 0
• CSF1R 0
• FTO 0
• PKM2 0
• SGLT2 0
• CD38 0
• COX-2 0
• DPP-4 0
• G6PD 0
• IDO1 0
• PDE4 0
• PTEN 0
• YAP 0
• ALK 0
• APP 0
• ATM 0
• BACE1 0
• C9orf72 0

3889 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• U.S. Department of Veterans Affairs · I01

  Peripheral orexin agonists to improve motor function in a mouse model of Parkinson’s Disease

  Minneapolis Va Medical Center· Minneapolis, Egyesült Államok· until 2030. szept.

• U.S. Department of Veterans Affairs · I01

  Clinical and Neuropathological Characterization of Parkinsonism Related to TBI in Veterans (CANPARK-TBI)

  James J Peters Va Medical Center· Bronx, Egyesült Államok· until 2030. szept.

• NIH NEI · R01

  Retinal Cell Loss in Diabetic Retinopathy

  Wayne State University· Detroit, Egyesült Államok· 387 500 USD awarded in fiscal year 2026· until 2030. máj.

• NIH NIDDK · F31

  Skeletal muscle MIRO1 Mediates Insulin Resistance and Muscular Complications in Type 2 Diabetes

  University of Oklahoma Hlth Sciences Ctr· Oklahoma City, Egyesült Államok· 50 114 USD awarded in fiscal year 2026· until 2028. szept.

• NIH NCI · F31

  Deciphering RNA Zipcodes: A Novel Framework for Subcellular Localization Element Annotation

  Baylor College of Medicine· Houston, Egyesült Államok· 50 114 USD awarded in fiscal year 2026· until 2029. szept.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Multimodal AI-based Clinical prOgnostic Models for PArkinson's Symptoms progression and Subtyping (mAIcompass)

  Stichting Amsterdam Umc· Amsterdam, Hollandia· EU contribution 435 842 EUR· until 2030. nov.· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Curation, Integration, Modelling and Rational Design of Small Molecule Amyloid Inhibitors (AmyStoppers)

  Vilniaus Universitetas· Vilnius, Litvánia· EU contribution 196 976 EUR· until 2029. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Multi-scAle high-order neTwork modelling in the stUdy of human aging: A data-dRiven perspectIve using Topology and geometrY (MATURITY)

  Institut National de Recherche En Informatique Et Automatique· Le Chesnay Cedex, Franciaország· EU contribution 226 421 EUR· until 2029. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  ENGINEERING NANOPARTICLE-WATER COUPLING; ionic, hypoxic, logic and molecular contrast switches (WATERGATING)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, Egyesült Királyság· EU contribution 2 113 066 EUR· until 2031. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Single-vesicle PlAtform for Real-Time detection of membrane-catalyzed Aggregation and transmission (SPARTA)

  Aarhus Universitet· Aarhus C, Dánia· EU contribution 1 500 000 EUR· until 2031. nov.

  The disease is named only in the funder's project summary, not in the title.

10 of 1408 running projects, newest first. Listed amounts together: 777,6 M USD + 184,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  High-Dose Ambroxol in GBA1-Related Parkinson

  NCT06193421· Agyany Pharma LTD· Frissítve: 2026. nov. 9.

  “Sponsor's decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Robotic Gait Rehabilitation in Parkinson's Disease

  NCT05218187· Indiana University· Frissítve: 2026. nov. 5.

  “The PI was no longer able to successfully recruit participants and funding was depleted.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Tapping Test and the Archimedean Spiral for the Differential Diagnosis of Tremor. Machine Learning Approach

  NCT06378619· Consorci Sanitari de l'Alt Penedès i Garraf· Frissítve: 2026. okt. 28.

  “Poor recruitment”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  NCT02897063· Vanderbilt University Medical Center· Frissítve: 2026. okt. 23.

  “enrollment goal was not met.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Disease

  NCT06003608· Nimble Science Ltd.· Frissítve: 2026. okt. 20.

  “Study recruitment phase exceeded the time allotted”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Terazosin And Metabolic Energetics in Parkinson's Disease

  NCT07464028· Ergun Y. Uc· Frissítve: 2026. okt. 9.

  “Study not funded”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Terazosin And Metabolic Engagement in Parkinson's Disease

  NCT07288450· Nandakumar Narayanan· Frissítve: 2026. okt. 7.

  “Not Funded”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease

  NCT07313176· Britannia Pharmaceuticals Ltd.· Frissítve: 2026. okt. 2.

  “Following a reassessment, it was concluded that continuation of the study would no longer achieve its scientific objectives originally set out for the study.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  The Parkinson's Disease Case-Control Study

  NCT06848192· Westlake University· Frissítve: 2026. szept. 29.

  “Due to challenges in obtaining faecal samples from patients with Parkinson's disease, a population frequently affected by constipation.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Sensory Filtering in the Human Basal Ganglia as a Mechanism of Parkinson's Disease

  NCT05482126· University of Alabama at Birmingham· Frissítve: 2026. szept. 24.

  “Suspending since no longer working participants at this time or enrolling new ones.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle Control

  NCT07056361· Jorge Gonzalez-Martinez· Forrás

• Closed Loop DBS Implanted RC+S Study

  NCT03815656· Dennis Turner, M.D.· Forrás

• DBS Imaging-based vs. Threshold Assessment-based Programming

  NCT06223399· Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)· Forrás

• Identification of Cognitive and Motor Changes in Individuals With and Without Parkinson's Disease Using Hemoencephalography

  NCT07931677· Federal University of Uberlandia· Forrás

• RehaBEElitation - Serious Game-Based Experimental Protocol to Improve Manual Dexterity in Individuals With Parkinson's Disease

  NCT07928050· Federal University of Uberlandia· Forrás

• Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease

  NCT07781644· Hoffmann-La Roche· Forrás

• An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

  NCT06996652· Yale University· Forrás

• Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

  NCT07642908· University of Michigan· Forrás

• Voluntary Activation During Isokinetic Contractions in Subjects With Neuromotor Disorders

  NCT04607174· Istituto Auxologico Italiano· Forrás

• Mobility in Daily Life and Falls in Parkinson's Disease: Potential for Rehabilitation

  NCT04897256· Oregon Health and Science University· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 25
• Organoids 19
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 15
• Gene Expression Profiling 76
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 7
• Exome Sequencing 12
• Proteomics 70
• Metabolomics 35
• Mass Spectrometry 12
• Flow Cytometry 4
• Immunohistochemistry 50
• Liquid Biopsy 3
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 103
• Magnetic Resonance Imaging 369
• Machine Learning 141
• Deep Learning 72
• Cohort Studies 186
• Genome-Wide Association Study 83

• Association between the Frequency of Individual Outdoor Activity and Risk of Incident Dementia in an Elderly Population in China: A National Cohort Study.

  Neuroepidemiology, 2026. nov.

• Subjective cognitive decline as an early marker of cognitive impairment in Parkinson's disease.

  J Neurol, 2026. nov.

• Drug-Specific Associations of Angiotensin Receptor Blockers With Parkinson's Disease Risk in a Multicenter Electronic Health Record Cohort.

  Fundam Clin Pharmacol, 2026. nov.

• Baseline CSF and plasma glucocerebrosidase activity predict longitudinal cognitive decline in Parkinson's disease: A PPMI longitudinal cohort study.

  J Clin Neurosci, 2026. okt.

• Physical Activity and Motor and Cognitive Progression in Parkinson Disease: A Longitudinal Cohort Study.

  Neurology, 2026. okt.

• Genetic findings in a Turkish clinical cohort with hereditary Parkinson's disease.

  Neurogenetics, 2026. okt.

• Anti-osteoporosis medications in persons with and without Parkinson disease in Finland.

  Arch Osteoporos, 2026. okt.

• GLP1R expression and Parkinson's disease and related disorders in GLP-1 receptor agonist-treated type 2 diabetes.

  Brain, 2026. okt.

• Association between C9orf72 G4C2 repeat length and idiopathic Parkinson's disease in a Turkish cohort.

  Neurol Sci, 2026. okt.

• Common MC1R Variants and Parkinson Disease Progression.

  JAMA Neurol, 2026. okt.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.